DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/0c2bf3/chinas_heparin_in) has announced the addition of the "China's Heparin Industry Report, 2010-2011" report to their offering.
With richness in heparin materials and the quality of heparin API getting accredited by the international community, China has become one of the largest heparin API producers and exporters in the world. In 2010, there were 24 heparin API manufacturers with the heparin sodium API production license granted by SFDA in China, with the export volume of heparin API reaching 15.9 trillion units, a 52.1% market share globally.
Europe and America are the major export destinations of heparin API made in China. From January to July of 2011, heparin and heparinate made in China were exported to 44 countries. In terms of export volume, the top 5 export destinations were France, Germany, America, Austria and Italy, with the combined export volume standing at 83.7%.
It is required to obtain CEP certification of EU or FDA authentication of the US for companies to access into the European and American markets. Due to the stringent authentication criterion, many unqualified enterprises are forced to withdraw from the market. As of August, 2011, China had 6 CEP certified heparin API producers and 2 FDA certified ones.
Restricted by the technology, the LMW heparin preparation market of China is dominated by foreign brands.
Key Topics Covered By "China's Heparin Industry Report, 2010-2011":
- Profile of Heparin Industry
- International Operating Environment of Heparin Industry
- Current Development of China Heparin API Industry
- Current Development of China Heparin Preparation Industry
- Import & Export
- Heparin Manufacturers in China
Companies Mentioned:
- Changzhou Qianhong Bio-Pharma Co., Ltd
- Hebei Changshan Biochemical Pharmaceutical
- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
- Shenzhen Hepalink Pharmaceutical
- Tianjin Chase Sun Pharmaceutical
- Yantai Dongcheng Biochemicals Co., Ltd
- Wanbang Biopharmaceuticals
For more information visit http://www.researchandmarkets.com/research/0c2bf3/chinas_heparin_in